United Therapeutics Corporation

Stock Chart, Company Information, and Scan Results

$564.29(as of May 20, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

United Therapeutics Corporation Company Information, Fundamentals, and Technical Indicators

Stock Price$564.29
Ticker SymbolUTHR
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees1,400
CountyUSA
Market Cap$24,066.9M
EBIDTA1,548.5M
10-Day Moving Average574.02
P/E Ratio20.78
20-Day Moving Average572.84
Forward P/E Ratio20.58
50-Day Moving Average562.64
Earnings per Share27.00
200-Day Moving Average472.04
Profit Margin35.18%
RSI48.50
Shares Outstanding42.4M
ATR15.11
52-Week High609.35
Volume372,477
52-Week Low272.12
Most Recent Support Level561.20
Book Value5,901.1M
Most Recent Resistance Level584.71
P/B Ratio4.53
Upper Keltner606.84
P/S Ratio8.44
Lower Keltner538.84
Debt-to-Equity Ratio606.84
Next Earnings Date07/28/2026
Cash Surplus475.1M
Next Ex-Dividend DateUnknown

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation In Our Stock Scanner

As of May 20, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.